Ipilimumab vs Muromonab-Cd3
Ipilimumab vs Muromonab-Cd3: Overview
This comparison examines the pharmacological differences between Ipilimumab and Muromonab-Cd3.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Ipilimumab β Antibody; Muromonab-Cd3 β Unknown.